{
    "nctId": "NCT01664494",
    "briefTitle": "An Observational Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer, Colon Cancer in the Adjuvant Setting, Advanced Gastric Cancer or Breast Cancer",
    "officialTitle": "A Non-Interventional Trial of Xeloda in Metastatic Colorectal Cancer, Adjuvant Colon Cancer, Advanced Gastric Cancer and Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Colorectal Cancer, Gastric Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 563,
    "primaryOutcomeMeasure": "Number of Participants With Routine Clinical Use of Capecitabine as Per the Line of Treatment",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with metastatic colorectal cancer, colon cancer in the adjuvant setting, advanced gastric cancer or breast cancer who are candidates for receiving Xeloda according to product label\n\nExclusion Criteria:\n\n* Contraindications according to label and off-label use",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}